Revolution Medicines (NASDAQ:RVMD) Insider Sells $1,275,301.26 in Stock

Posted by Brian Himes on Oct 4th, 2026

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Alan Sandler sold 6,309 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the transaction, the insider owned 52,559 shares of the company’s stock, valued at $10,624,276.26. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Revolution Medicines Trading Up 0.4%

Shares of RVMD opened at $206.64 on Friday. The firm’s 50-day moving average price is $202.80 and its 200-day moving average price is $166.67. The firm has a market capitalization of $44.29 billion, a price-to-earnings ratio of -23.43 and a beta of 1.40. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 1-year low of $45.72 and a 1-year high of $224.31.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the firm posted ($1.31) EPS. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -8.87 EPS for the current year.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds have recently added to or reduced their stakes in the stock. Burkett Financial Services LLC bought a new position in shares of Revolution Medicines during the third quarter valued at $27,000. QRG Capital Management Inc. increased its stake in Revolution Medicines by 31.6% during the 2nd quarter. QRG Capital Management Inc. now owns 8,083 shares of the company’s stock valued at $1,514,000 after purchasing an additional 1,943 shares in the last quarter. Andra AP fonden raised its holdings in Revolution Medicines by 69.9% in the second quarter. Andra AP fonden now owns 28,200 shares of the company’s stock worth $5,281,000 after buying an additional 11,600 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Revolution Medicines in the second quarter worth approximately $626,000. Finally, MCF Advisors LLC bought a new position in shares of Revolution Medicines in the second quarter worth approximately $78,000. 94.34% of the stock is owned by institutional investors.

Analyst Ratings Changes

RVMD has been the subject of a number of research analyst reports. Morgan Stanley began coverage on Revolution Medicines in a research note on Thursday, September 10th. They issued an “overweight” rating and a $255.00 target price for the company. Guggenheim upped their price target on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Friday, August 28th. Brookline Capital Markets started coverage on Revolution Medicines in a research report on Monday, September 28th. They set a “buy” rating and a $318.00 price objective for the company. Needham & Company LLC upped their target price on shares of Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Finally, Wedbush boosted their price objective on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $234.33.

Get Our Latest Analysis on Revolution Medicines

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.